Evommune (EVMN) Treasury Shares (2024 - 2025)
Evommune (EVMN) posted quarterly Treasury Shares of $328318.0 for Q4 2025, down 99.72% year-over-year from $116.7 million in Q4 2024, and down 99.79% quarter-over-quarter from $157.7 million in Q3 2025.
Powered by 
Analysis
Evommune (EVMN) Treasury Shares (2024 - 2025) Analysis & Trends
Evommune (EVMN) has reported Treasury Shares for 2 consecutive years, with $328318.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Treasury Shares fell 99.72% year-over-year to $328318.0; the TTM figure through Dec 2025 stood at $328318.0 (down 99.72% YoY), while the FY2025 annual figure was $328318.0, down 99.72% from the prior year.
- Treasury Shares declined to $328318.0 in Q4 2025 per EVMN's latest filing, from $157.7 million in the prior quarter.
- Across five years, Treasury Shares topped out at $157.7 million in Q3 2025 and bottomed at $328318.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 2.72 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Evommune | 445.37 Mn | 244.58 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 157.66 Mn |
| Sep 30, 2025 | 157.66 Mn |
| Jun 30, 2025 | 157.66 Mn |
| Jun 30, 2025 | 157.66 Mn |
| Mar 31, 2025 | 116.72 Mn |
| Mar 31, 2025 | 116.72 Mn |
| Dec 31, 2024 | 116.72 Mn |
| Dec 31, 2024 | 116.72 Mn |
| Sep 30, 2024 | 85.22 Mn |
| Sep 30, 2024 | 85.22 Mn |